Literature DB >> 9323147

Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma.

C J O'Brien1, K Petersen-Schaefer, G N Stevens, P C Bass, P Tew, V J Gebski, J F Thompson, W H McCarthy.   

Abstract

BACKGROUND: Regional recurrence remains a problem in the management of patients with metastatic malignant melanoma in the cervical lymph nodes and parotid. In this study, the influence of the number of positive nodes, extracapsular spread, and the use of adjuvant radiotherapy on regional control and survival were analyzed.
METHODS: A non-randomized, prospectively documented series of 143 patients with histologically positive nodes in the neck or parotid was analyzed. There were 152 dissected necks or parotids: 45 of these received postoperative radiotherapy, 6 x 5.5 Gy fractions over 3 weeks; 107 were not irradiated.
RESULTS: The regional recurrence rate was 6.5% in the irradiated group, compared with 18.7% in the non-irradiated group (p = .055). The irradiated group, however, had more extensive nodal involvement than the non-irradiated group: 65% had two or more positive nodes, and 48% had extracapsular spread, compared with 40% and 19%, respectively, in the non-irradiated group. Survival was significantly worse when there was extracapsular spread (p < .05) or multiple node involvement (p < .01). By multivariate analysis, the use of adjuvant radiotherapy was associated with a trend toward improved regional control (p = .065), but survival was not improved.
CONCLUSIONS: Adjuvant radiotherapy was associated with improved control of metastatic malignant melanoma in the neck and parotid; however, statistical significance was not reached. A prospective trial should be supported to clarify this question.

Entities:  

Mesh:

Year:  1997        PMID: 9323147     DOI: 10.1002/(sici)1097-0347(199710)19:7<589::aid-hed5>3.0.co;2-3

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  12 in total

Review 1.  Melanoma of the head and neck.

Authors:  Terry A Day; Joshua D Hornig; Anand K Sharma; Frank Brescia; M Boyd Gillespie; Deanne Lathers
Journal:  Curr Treat Options Oncol       Date:  2005-01

Review 2.  Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites.

Authors:  Amod A Sarnaik; Jonathan S Zager; Vernon K Sondak
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

3.  A retrospective analysis of the role of adjuvant radiotherapy in the treatment of cutaneous melanoma.

Authors:  Aaron Baker; Fabian Camacho; Genevieve Andrews; Heath Mackley
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

4.  [Adjuvant radiotherapy following lymphadenectomy for malignant melanoma significantly improves local control].

Authors:  G Goldner
Journal:  Strahlenther Onkol       Date:  2013-01       Impact factor: 3.621

Review 5.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

Review 6.  [Primary malignant melanoma of the parotid gland: a case report and review of the literature].

Authors:  H Maier; G Mühlmeier; K Kraft; N M Blumstein; M Tisch
Journal:  HNO       Date:  2008-06       Impact factor: 1.284

7.  Parotid melanoma of unknown primary.

Authors:  Jeffrey F Scott; Cheryl L Thompson; Ritva Vyas; Kord Honda; Chad Zender; Rod Rezaee; Pierre Lavertu; Henry Koon; Kevin D Cooper; Meg R Gerstenblith
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-13       Impact factor: 4.553

8.  Role of radiotherapy in melanoma management.

Authors:  Primoz Strojan
Journal:  Radiol Oncol       Date:  2010-03-18       Impact factor: 2.991

Review 9.  Melanoma: adjuvant therapy and other treatment options.

Authors:  Alicia Terando; Michael S Sabel; Vernon K Sondak
Journal:  Curr Treat Options Oncol       Date:  2003-06

Review 10.  Early stage (I, II, III) melanoma.

Authors:  V K Sondak; M I Ross; L M Schuchter
Journal:  Curr Treat Options Oncol       Date:  2001-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.